Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.48 |
| ▸ | STS | P08842 | 14/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879688 | 0.87 | CYP19A1 (0.59) | CYP19A1STS | |
| SCHEMBL16879691 | 0.84 | CYP19A1 (0.45) | CYP19A1STSCA1CA2CA9 | |
| SCHEMBL16879686 | 0.83 | CYP19A1 (0.45) | CYP19A1STSCA1CA2CA9 | |
| SCHEMBL16879690 | 0.80 | STS (0.48) | CYP19A1STS | |
| SCHEMBL16879489 | 0.79 | STS (0.45) | CYP19A1STSCA1CA2CA9 | |
| SCHEMBL16879838 | 0.78 | CYP19A1 (0.46) | CYP19A1STS | |
| SCHEMBL16879755 | 0.76 | CYP19A1 (0.35) | CYP19A1STSCA2 | |
| SCHEMBL16879494 | 0.75 | CYP19A1 (0.57) | CYP19A1STS | |
| SCHEMBL16879730 | 0.75 | SCN9A (0.33) | CYP19A1STSMKNK1 | |
| SCHEMBL16879683 | 0.75 | CYP19A1 (0.39) | CYP19A1STSCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089966-B1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | ESTRYX PHARMA LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-9682941-B2 | Substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase | ESTRYX PHARMA LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2017-01-05 | — | — | US | disclosed |
| EP-3089966-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | Beaufour Ipsen Tianjin Pharmaceutical Co., Ltd (CN) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015100609-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | CYP19A1, SULT2A1, STS | CYP19A1 1/4885STS 3/4885CA1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.